Zydus receives FDA final approval for Diroximel fumarate delayed-release capsules, 231 mg
Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis
Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis
The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations
Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets are indicated for the treatment of human immunodeficiency virus infection in adults and pediatric patients weighing at least 25 kg
Subscribe To Our Newsletter & Stay Updated